Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer
Status:
Terminated
Trial end date:
2019-11-11
Target enrollment:
Participant gender:
Summary
The investigator is developing an immune therapy against pancreatic cancer. Immune cells,
known as "T cells with tumor killing capacity", are involved in this immune therapy. In mice
with pancreatic cance there is evidence that one tetanus toxoid (TT) vaccination (that
patients receive from childhood) combined with Gemcitabine activates these killer T cells.
(Gemcitabine improves T cell responses) These killer T cells are able to destroy tumor cells
uploaded with TT protein (such studies are planned in future clinical trials). The goal of
this study is to test whether one TT vaccination combined with Gemcitabine treatment
activates the same T cells in pancreatic cancer patients.
Phase:
Phase 2
Details
Lead Sponsor:
Albert Einstein College of Medicine
Collaborators:
Pancreatic Cancer Action Network Pancreatic Cancer Action Network (PCAN)